Search

Displaying results 2731 - 2740 of 7186 in total
  1. Drug

    Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine

    go.drugbank.com/drugs/DB10061
    ApprovedInvestigational

    Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine is used to prevent invasive meningococcal disease, which is caused by bacteria _Neisseria meningitidis_ entering … the bloodstream and invading the blood-brain barrier to cause a variety of infections such as septicemia, meningitis, and pneumonia.

  2. Drug

    Sarilumab

    go.drugbank.com/drugs/DB11767
    ApprovedInvestigational

    [A27262] Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe rheumatoid … [A27264] Subcutaneous administration of sarilumab has been shown to decrease acute-phase reactant levels and improve clinical RA symptoms.[A27263]

  3. Drug

    CGX-1321

    go.drugbank.com/drugs/DB17491
    Investigational

    CGX-1321 is a porcupine inhibitor that affects Wnt production and can block Wnt downstream signaling.[A257038]

  4. Drug

    Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen

    go.drugbank.com/drugs/DB10076
    Approved

    grown in a semi-synthetic medium, covalently bound to tetanus toxoid [L1007]. … The vaccine contains the *Haemophilus influenzae* type b capsular polysaccharide (polyribosyl-ribitol-phosphate, PRP), a high-molecular-weight polymer prepared from the *H. influenzae* type b strain 1482

    Mixtures: PENTAXİM 0,5 ML IM ENJEKSİYONLUK SÜSPANSİYON İÇİN TOZ İÇEREN FLAKON VE SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADET
  5. Drug

    Desoxycorticosterone pivalate

    go.drugbank.com/drugs/DB01134
    ExperimentalVet approved

    Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.

  6. Drug

    Defactinib

    go.drugbank.com/drugs/DB12282
    ApprovedInvestigational

    [L53208,A273943] Defactinib was approved by the US FDA in May 2025 in a co-package alongside [avutometinib] (called Avmapki Fakzynja) for the treatment of recurrent KRAS-mutated low-grade serous ovarian … important for the integrin-mediated activation of several downstream signal transduction pathways, including those involving RAS/MEK/ERK and PI3K/Akt, and its upregulation is a key resistance mechanism to

    Mixtures: Avmapki Fakzynja Co-packSynonyms: N-methyl-4-[[4-[[3-[methyl(methylsulfonyl)amino]pyrazin-2-yl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzamide
  7. Drug

    Prenylamine

    go.drugbank.com/drugs/DB04825
    ApprovedWithdrawn

    Prenylamine was withdrawn from the Canadian, US, and UK markets in 1988 due to concerns regarding cardiac arrhythmias.

    Synonyms: N-(3,3-Diphenylpropyl)-alpha-methylphenaethylamin, N-(3,3-Diphenylpropyl)-alpha-methylphenethylamine
  8. Drug

    SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer (B.1.351-B.1.1.7 strains)

    go.drugbank.com/drugs/DB18705
    Approved

    [L48902] It is intended to elicit protection against Omicron XBB.1.5, one of the dominant circulating SARS-CoV-2 subvariants in 2023. … [A262551] It is produced using recombinant DNA technology in CHO cell lines and is marketed by Hipra Human Health S.L. for the European market.

  9. Drug

    Imelasomeran

    go.drugbank.com/drugs/DB17090
    ApprovedInvestigational

    Imelasomeran was first approved in Canada on September 1, 2022, as one-half of Moderna's Spikevax Bivalent COVID-19 mRNA vaccine. It encodes for the viral spike protein of the Omicron BA.1 variant of SARS-CoV-2, a particularly infectious...

  10. Drug

    Oxyphenbutazone

    go.drugbank.com/drugs/DB03585
    ApprovedWithdrawn

    Oxyphenbutazone was withdrawn from the Canadian market in March 1985 due to concerns regarding bone marrow suppression.